# **Supporting Information**

# Caspase-1 Inhibitors from an Extremophilic Fungus that Target Specific Leukemia Cell Lines

Andrea A. Stierle,\* Donald B. Stierle,\* and Teri Girtsman

Department of Biomedical and Pharmaceutical Sciences, The University of Montana Missoula, Montana 59812

## **Table of Contents**

- S3 <sup>1</sup>H NMR of Berkazaphilone A (1), 300 MHz, CDCl<sub>3</sub>
- S4 <sup>13</sup>C NMR of Berkazaphilone A (1), 75 MHz, CDCl<sub>3</sub>
- S5 COSY of Berkazaphilone A (1), 300 MHz, CDCl<sub>3</sub>
- S6 HMBC of Berkazaphilone A (1), 300 MHz, CDCl<sub>3</sub>
- S7 <sup>1</sup>H NMR of Berkazaphilone B (**2**), 300 MHz, CDCl<sub>3</sub>
- S8 <sup>13</sup>C NMR of Berkazaphilone B (**2**), 75 MHz, CDCl<sub>3</sub>
- S9 COSY of Berkazaphilone B (2), 300 MHz, CDCl<sub>3</sub>
- S10 HMBC of Berkazaphilone B (2), 300 MHz, CDCl<sub>3</sub>
- S11 <sup>1</sup>H NMR of Berkazaphilone C (4), 300 MHz, CDCl<sub>3</sub>
- S12 <sup>13</sup>C NMR of Berkazaphilone C (4), 75 MHz, CDCl<sub>3</sub>
- S13 Spectral data for compounds 6, 7, and 8
- S14 Spectral Data for Compounds 9, 10, 11, and 12
- S16 <sup>1</sup>H NMR of Berkedienoic acid (**13**), 300 MHz, CDCl<sub>3</sub>
- S17 <sup>13</sup>C NMR of Berkedienoic acid (**13**), 75 MHz, CDCl<sub>3</sub>

- S18 COSY of Berkedienoic acid (13), 300 MHz, CDCl<sub>3</sub>
- S19 HMBC of Berkedienoic acid (13), 300 MHz, CDCl<sub>3</sub>
- S20 <sup>1</sup>H NMR of Berkedienolactone (**15**), 300 MHz, CDCl<sub>3</sub>
- S21 <sup>13</sup>C NMR of Berkedienolactone (**15**), 75 MHz, CDCl<sub>3</sub>
- S22 COSY of Berkedienolactone (15), 300 MHz, CDCl<sub>3</sub>
- S23 HMBC of Berkedienolactone (15), 300 MHz, CDCl<sub>3</sub>
- S24 NCI cell line data for berkazaphilone B (2)
- S25 NCI cell line data for berkazaphilone C (4)
- S26 NCI cell line data for penisimplicissin (8)





S4 <sup>13</sup>C NMR of Berkazaphilone A (1), 75 MHz, CDCl<sub>3</sub>



S5 COSY of Berkazaphilone A (1)



S6 HMBC of Berkazaphilone A (1)





S8 <sup>13</sup>C NMR of Berkazaphilone B (**2**), 75 MHz, CDCl<sub>3</sub>



S9 COSY of Berkazaphilone B (2)



S10 HMBC of Berkazaphilone B (2)



S11  $^{1}$ H NMR of Berkazaphilone C (4) , 300 MHz, CDCl<sub>3</sub>



S12 <sup>13</sup>C NMR of Berkazaphilone C(4), 75 MHz, CDCl<sub>3</sub>

### Spectral Data for Compounds 6, 7 and 8

**Vermistatin** (6):  $[\alpha]_{D}^{25}$  -10.5° (c 0.0154, MeOH/CHCl<sub>3</sub>, 1:1).

**Dihydrovermistatin** (7): yellow solid,  $[\alpha]^{25}_{D}$  -28.6° (c 0.0091 CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ) 305 (3.35), 249 (3.57); IR (CHCl<sub>3</sub>)  $\nu_{max}$  3013, 2966, 1770, 1668, 1506, 1238, 1120, 911 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.41 (s, 1H, H-2'), 6.96 (d, J = 2.0 Hz, H-7), 6.66 (d, 1H, J = 2.0 Hz, H-5), 6.44 (s, 1H, H-3), 6.17 (s, 1H, H-5'), 3.85 (s, 3H, C-6 OCH<sub>3</sub>), 3.77 (s, 3H, C-4 OCH<sub>3</sub>), 2.45 (t, J = 7.4 Hz, H-7'), 1.62 (m, 1H, J = 7.4 Hz, H-8'), 0.95 (t, 1H, J = 7.4 Hz, H-9'); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  177.0 (C-4'), 170.0 (C-1), 169.4 (C-6'), 163.0 (C-6), 154.8 (C-4), 154.4 (C-2'), 129.3 (C-8), 127.7 (C-9), 123.3 (C-3'), 114.4 (C-5'), 105.1 (C-5), 98.9 (C-7), 73.5 (C-3), 56.0 (C-6 OCH<sub>3</sub>), 55.8 (C-4 OCH<sub>3</sub>), 35.2 (C-7'), 19.9 (C-8'), 13.4 (C-9'); EIMS *m*/*z* [M]<sup>+</sup> 330(100), 271(40), 217 (70); HREIMS *m*/*z* 330.1108 [M]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>18</sub>O<sub>6</sub>, 330.1103).

**Penisimplicissin** (8): yellow solid,  $[\alpha]^{25}_{D}$  -78.2° (c 0.0118, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{max}$  (log ε) 448 (3.97), 310 (3.45); IR (CHCl<sub>3</sub>)  $\nu_{max}$  3011, 1768, 1668, 1509, 1362, 1156, 910 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.41 (s, 1H, H-2'), 6.95 (d, *J* = 2.0 Hz, H-7), 6.65 (d, *J* = 2.0 Hz, H-5), 6.43 (s, 1H, H-3), 6.17 (s, 1H, H-5'), 3.85 (s, 3H, C-6 OCH<sub>3</sub>), 3.76 (s, 3H, C-4 OCH<sub>3</sub>), 2.44 (s, 3H, H-7'); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 176.9 (C-4'), 170.4 (C-1), 166.0 (C-6'), 163.0 (C-6), 154.9 (C-4), 154.4 (C-2'), 129.3 (C-8), 127.7 (C-9), 123.3 (C-3'), 115.0 (C-5'), 105.1 (C-5), 98.9 (C-7), 73.5 (C-3), 56.0 (C-6 OCH<sub>3</sub>), 55.8 (C-4 OCH<sub>3</sub>), 19.6 (C-7'); EIMS *m*/*z* [M]<sup>+</sup> 302(100), 259 (30), 217 (30), 165 (32); HREIMS *m*/*z* 302.0787 [M]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>14</sub>O<sub>6</sub>, 302.0790).

### Spectral Data for Compounds 9, 10, 11, and 12

**Compound 9**: solid,  $[\alpha]^{25}_{D}$  +20.8° (c 0.014, MeOH); <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  9.77 (1H, s, H-12), 6.22 (1H, s, H-5), 4.22 (1H, m, H-10), 4.04 (2H, s, H-7), 2.72 (1H, m, H-9), 2.61 (1H, m, H-9), 2.01 (3H, s, H-13), 1.19 (3H, d, *J* = 6.3 Hz, H-11); <sup>13</sup>C NMR (CD<sub>3</sub>OD)  $\delta$  208.8 (C, C-8), 195.1 (CH, C-12), 165.2 (C, C-2), 164.6 (C, C-4), 139.1 (C, C-6), 113.8 (C, C-1), 111.9 (C, C-3), 111.5 (CH, C-5), 65.3 (CH, C-10), 52.1 (CH<sub>2</sub>, C-9), 47.7 (CH<sub>2</sub>, C-7), 23.8 (CH<sub>3</sub>, C-11), 7.4 (CH<sub>3</sub>, C-13); EIMS *m*/*z* 252 (4), 234 (25), 166 (100); HREIMS *m*/*z* 252.1003 [M]<sup>+</sup> (calcd for C<sub>13</sub>H<sub>16</sub>O<sub>5</sub>, 252.0998).

**Chiral derivatization of compound 9**. Compound **9** (1.0 mg) was dissolved in dry pyridine (100 µL) and either the R or S stereoisomer of  $\alpha$ -methoxy- $\alpha$ -trifluoromethylphenylacetyl chloride (6 µL) added. The mixtures were stirred for 24 hours under nitrogen. After that time, MeOH (400 µL), was added and the solvents removed. The reaction mixtures were then each passed through a small Si gel column and eluted with CH<sub>2</sub>Cl<sub>2</sub> to give the R- and S- MTPA esters, **10**. (**R**)-**MTPA ester**- <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  9.60 (1 H, s), 7.45 (5 H, m, aromatics), 6.85 (1 H, s), 5.55 (1 H, m), 3.60 (2H, s), 3.51 (3 H, s, OCH<sub>3</sub>), 3.03 (1 H, dd, *J* = 17.2, 7.9 Hz), 2.85 (1 H, dd, *J* = 17.2, 5.0 Hz), 1.81 (3 H, s), 1.32 (3 H, d, *J* = 6.4 Hz).

(S)-MTPA ester- <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.57 (1 H, s), 7.41 (5 H, m, aromatics), 6.80 (1 H, s), 5.59 (1 H, m), 3.590 (2 H, s), 3.50 (3H, s, OCH<sub>3</sub>), 2.96 (1 H, dd, *J* = 17.2, 8.2 Hz), 2.80 (1 H, dd, *J* = 17.2, 4.7 Hz), 1.80 (3 H, s), 1.39 (1 H, d, *J* = 6.4 Hz).

Methyl paraconic acid (11): solid,  $[\alpha]^{25}{}_{D}$  +29.1° (c 0.0088, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) ν<sub>max</sub> 3027 (broad), 2981, 2939, 1774, 1716, 1178, 1025 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.50 (1H, t, *J* = 9.0 Hz, H-5), 4.29 (1H, t, *J* = 9.0 Hz, H-5), 3.12 (1H, q, *J* = 9.0 Hz, H-3), 2.88 (1H, m, H-2), 1.37 (3H, d, *J* = 6.9 Hz, H-6); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.5 (C, C-1), 175.6 (C, C-4), 66.4 (CH<sub>2</sub>, C-5), 47.7 (CH, C-3), 37.8 (CH, C-2), 14.6 (CH<sub>3</sub>, C-6); EIMS *m*/*z* 144 [M]<sup>+</sup>.

**Methylation of 11:** Compound 11, (2.0 mg) was dissolved in  $Et_2O$  (200 µL) and a solution of  $CH_2N_2$  in  $Et_2O$  was added drop wise until the yellow color persisted. The solution was stirred for 5 minutes and the solvent removed under a stream of  $N_2$  to yield the methyl ester **12** (2.0 mg).

**Compound 12**: <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  4.46 (1H, t, *J* = 9.2 Hz, H-5), 4.24 (1H, t, *J* = 9.2 Hz, H-5), 3.76 (3H, s, OCH<sub>3</sub>), 3.07 (1H, dt, *J* = 10.2, 9.2 Hz, H-3), 2.85 (1H, dq, *J* = 10.2, 7.1 Hz, H-2), 1.34 (3H, d, *J* = 7.1 Hz, H-6); HREIMS *m*/*z* 159.0657 [M+H]<sup>+</sup> (calcd for C<sub>7</sub>H<sub>11</sub>O<sub>4</sub>, 159.0686).







S18 COSY of Berkedienoic acid (13), 300 MHz, CDCl<sub>3</sub>



S19 HMBC of Berkedienoic acid (13), 300 MHz, CDCl<sub>3</sub>







S21 <sup>13</sup>C NMR of Berkedienolactone (**15**), 75 MHz, CDCl<sub>3</sub>



S22 COSY of Berkedienolactone (15), 300 MHz, CDCl<sub>3</sub>



S23 HMBC of Berkedienolactone (15), 300 MHz, CDCl<sub>3</sub>





	National Cancer Institute Deve	elopmental Therapeutics Program	NSC : D - 742359/1	Units :Molar	SSPL :0BCM	EXP. ID :0607NS84	
	Mean Graphs		Report Date :September 26, 2011		Test Date :July 17, 2006		
	Panel/Cell Line Log <sub>10</sub> GI50 GI50		Log <sub>10</sub> TGI TGI		Log <sub>10</sub> LC50 LC50		
	Leukemia CORF-CEM T-SEQUED RESOLUTION SECTOR SECTOR BIDA HIGH-8225 SR NOT-1452 HIGH-82	-672 -67233 -47338 -47438 - 488	> 4.00 +1.54 > 4.00 > 4.00 > 4.00	—	> 400 - 400 > 400 > 400 > 400		
		**************************************	* 400 * 4400 * 4400 * 4400 * 4400 * 4400		* 400 * 400 * 400 * 400 * 400 * 400 * 400		
		<pre>&gt; 400 &gt; 400 </pre>	> 4.00 > 4.00 > 4400 > 4400 > 4.00 > 4.00 > 4.00		> 400 > 400 > 400 > 400 > 400 > 400 > 400 > 400		
		**************************************	> 4.00 > 4.00 > 4.00 > 4.00 > 4.00 > 4.00 > 4.00		> -400 > -400 > -400 > -400 > -400 > -400		
		* 444 4444 * * * * * * * *	* 488 * 4488 * 44888 * 44888 * 448888 * 4488888 * 4488888 * 4488888 * 4488888 * 4488888 * 4488888 * 4488888 * 4488888 * 4488888 * 44888888 * 44888888 * 4488888 * 4488888 * 4488888 * 448888888 * 44888888 * 4488888 * 4488888 * 44888888 * 448888888 * 44888888 * 4488888 * 4488888 * 4488888888 * 44888888 * 4488888 * 4488888 * 44888888 * 448888888 * 44888888 * 44888888 * 44888888888 * 44888888 * 448888888888		> 480 - 488 > 4888 > 4888 > 488 > 488 > 488 > 488 > 488 > 488 > 488 > 488 > 48		
		* * * * * * * * * * * * * * * * * * *	* 400 * 400 * 400 * 400 * 400		> 400 +480 > 480 > 480 > 480 > 480 > 480 > 480		
		* * * * * * * * * * * * * * * * * * *	* 400 * 400 * 4400 * 4400 * 4400 * 4400 * 4400		> -400 > -400 		
	B6-145	<b>≍ :</b> 1:88	\$ \$88		\$ \$88		
	MOA-MB-231/ATCC HD53/8T BT-53/8T T-47D	488 44488 * * * * * *	> 400 > 400 > 400 > 400 > 400 > 400		> -400 > -400 > -400 > -400 > -400		
	MID Delta Range	-4.11 2.59 2.7	-4.01 0.63 0.64	<u> </u>	40	- <u></u>	
S	S 26 NCI cell line data for penisimplissicin (8).						